Al-Maraghi Aljazi, Shaath Rulan, Ford Katherine, Aamer Waleed, AlRayahi Jehan, Hussein Sura, Aliyev Elbay, Agrebi Nourhen, Kohailan Muhammad, Hubrack Satanay Z, Palaniswamy Sasirekha, Kennedy Adam D, DeBalsi Karen L, Elsea Sarah H, Benini Ruba, Ben-Omran Tawfeg, Lo Bernice, Akil Ammira S A, Fakhro Khalid A
Laboratory of Genomic Medicine, Research Section, Sidra Medicine, Doha P.O. Box 26999, Qatar.
College of Health and Life Sciences, Hamad Bin Khalifa University, Doha P.O. Box 34110, Qatar.
Int J Mol Sci. 2025 May 29;26(11):5213. doi: 10.3390/ijms26115213.
Pontocerebellar hypoplasia (PCH) encompasses a group of autosomal recessive neurodegenerative disorders marked by cerebellar and pontine atrophy. Multiple subtypes of PCH have been identified, among which the rare subtype PCH type 16 is caused by genetic variants. encodes an enzyme essential for inositol polyphosphate dephosphorylation, regulating calcium and iron homeostasis. We conducted genome sequencing on a proband from the consanguineous family, who presented with a severe neurodegenerative disorder, to identify the underlying cause of disease. A comprehensive clinical assessment in addition to neuroradiological findings are described. We performed the functional validation of the identified variant and conducted untargeted metabolomic analyses. The clinical and radiological assessment of the patient showed a congenital brain anomaly and neurodegenerative symptoms. Further genetic analysis identified a homozygous loss-of-function variant (c.1401del, p.Ser468Valfs10*) in providing molecular confirmation of a clinical PCH diagnosis. While real-time quantitative PCR (RT-qPCR) showed that gene expression was unaffected in the proband, Western blot analysis demonstrated reduced protein abundance, supporting a pathogenic role of the variant. Metabolomic profiling revealed elevated lipid levels and disrupted inositol metabolism, providing further insights into the disease mechanism. These findings establish the pathogenicity of the p.Ser468Valfs10* variant in and highlight inositol metabolism as a potential pathway involved in PCH16, advancing the understanding of the pathophysiology of the disease.
脑桥小脑发育不全(PCH)是一组常染色体隐性神经退行性疾病,其特征为小脑和脑桥萎缩。已鉴定出多种PCH亚型,其中罕见的16型PCH是由基因变异引起的。 编码一种对肌醇多磷酸去磷酸化至关重要的酶,调节钙和铁的稳态。我们对一个来自近亲家庭、患有严重神经退行性疾病的先证者进行了基因组测序,以确定疾病的潜在病因。除神经放射学检查结果外,还进行了全面的临床评估。我们对鉴定出的变异进行了功能验证,并进行了非靶向代谢组学分析。对该患者的临床和放射学评估显示出先天性脑异常和神经退行性症状。进一步的基因分析在 中鉴定出一个纯合功能丧失变异(c.1401del,p.Ser468Valfs10*),为临床PCH诊断提供了分子确认。虽然实时定量PCR(RT-qPCR)显示先证者中 基因表达未受影响,但蛋白质印迹分析表明蛋白质丰度降低,支持该变异的致病作用。代谢组学分析揭示脂质水平升高和肌醇代谢紊乱,为疾病机制提供了进一步的见解。这些发现确定了p.Ser468Valfs10*变异在 中的致病性,并突出了肌醇代谢作为PCH16潜在相关途径,推进了对该疾病病理生理学的理解。